What if AI could design custom medicines for diseases previously considered untreatable? MIT's new generative AI, BoltzGen, is a groundbreaking tool for engineering novel protein binders from scratch. Unlike models that only predict structure or design simple proteins, BoltzGen unifies both tasks and was rigorously validated across 26 challenging targets, including those deemed 'undruggable'. Its designs are also constrained by real-world physics and chemistry, ensuring the generated molecules are actually functional. This powerful open-source model could dramatically accelerate drug discovery and challenge the business models of private biotech firms. Its immediate applications include creating transformational drugs against major human diseases and developing molecular machines for tasks we haven't even imagined yet.